Recherchiere Firmenbekanntmachungen und finanzielle Kennzahlen
EU-Förderung (6.000.000 €): DECOMPENSATED CIRRHOSIS: IDENTIFIKATION VON NEUEN COMBINATORIAL THERAPIEEn BASIEREND AUF SYSTEMS APPROACHES Hor13.01.2020 EU-Rahmenprogramm für Forschung und Innovation "Horizont"
Auf einen Blick
Text
DECOMPENSATED CIRRHOSIS: IDENTIFIKATION VON NEUEN COMBINATORIAL THERAPIEEn BASIEREND AUF SYSTEMS APPROACHES
In 2013, cirrhosis was responsible for 1.2 million deaths worldwide. This mortality is mainly due to cirrhosis decompensation, i.e. development of ascites, hepatic encephalopathy, and/or gastrointestinal hemorrhage, and its progression to acute-on-chronic liver failure (ACLF). Patients with decompensated cirrhosis receive many treatments such as intravenous and oral absorbable antibiotics, oral non-absorbable antibiotics, albumin, proton-pump inhibitors, laxatives, diuretics, betablockers, vasoconstrictors, statins, anticoagulants, steroids and antiviral agents. Despite these multiple treatments, ACLF or mortality in patients with decompensation of cirrhosis remains high (15% at day 28, 28% at day 90) because of large interindividual variability in precipitating events, in clinical presentation and in response to treatment. This heterogeneity calls for treatment personalization according to underlying mechanisms. The objective of DECISION is to enhance our understanding, at systems level, of the pathophysiology of decompensation of cirrhosis leading to ACLF or death to decrease patients’ mortality at day 28. First, DECISION will improve our knowledge of the pathophysiology of decompensation of cirrhosis by integrating results of high-throughput multi-omic profiling with comprehensive clinical data from 2,200 fully characterized patients (more than 8,600 time points) with available standardized biological samples. Second, we will identify novel combinatorial therapies for patients with decompensation of cirrhosis to prevent death. We will refine these therapies in new and/or optimized animal models and then test the best combination in high risk patients in a phase II clinical trial built in DECISION. Third, we will develop 2 tests: one predicting outcome of patients with decompensation of cirrhosis when treated with standard treatment (prognostic test); and the other identifying patients who will respond to the novel combinatorial therapy (test for response).
Geförderte Unternehmen:
| Firmenname | Förderungssumme |
| Alma Mater Studiorum - Universita DI Bologna | 171.722 € |
| Assistance Publique Hopitaux de Paris | 420.472 € |
| Azienda Ospedaliera Citta Della Salute E Della Scienza DI Torino | 0,00 € |
| CONCENTRIS RESEARCH MANAGEMENT GmbH | 488.500 € |
| Commissariat a L Energie Atomique et aux Energies Alternatives | 345.000 € |
| EUROPEAN Association FOR THE STUDYOF THE LIVER | 50.000 € |
| Erasmus Universitair Medisch Centrum Rotterdam | 300.000 € |
| 1.233.650 € | |
| European Liver Patients Association | 50.000 € |
| Fundacio de Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi i Sunyer | 371.722 € |
| 382.500 € | |
| Hospital Clinic de Barcelona | 0,00 € |
| 105.472 € | |
| Institut National de la Sante et de la Recherche Medicale | 620.500 € |
| 0,00 € | |
| JOHANN WOLFGANG GOETHE-UNIVERSITAET FRANKFURT AM MAIN | 257.692 € |
| Nordic Bioscience A/S | 66.043 € |
| 105.472 € | |
| UNIVERSITAET MUENSTER | 121.530 € |
| UNIVERSITAETSKLINIKUM AACHEN | 275.874 € |
| Universita Degli Studi DI Padova | 42.500 € |
| Universita Degli Studi DI Torino | 105.472 € |
| Universitat de Barcelona | 120.000 € |
| Universite Paris Cite | 0,00 € |
| 105.879 € | |
| YH Youhealth AB | 260.000 € |
Quelle: https://cordis.europa.eu/project/id/847949
Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider.
Die Visualisierungen zu "Alma Mater Studiorum - Universita DI Bologna - EU-Förderung (6.000.000 €): DECOMPENSATED CIRRHOSIS: IDENTIFIKATION VON NEUEN COMBINATORIAL THERAPIEEn BASIEREND AUF SYSTEMS APPROACHES"
werden von
North Data
zur Weiterverwendung unter einer
Creative Commons Lizenz
zur Verfügung gestellt.
